The new prime DX assay is based on advanced molecular technology using hybridization capture NGS with UMIs. The test utilizes the Oncology Multi-Gene Variant Assay (GenePlus) which is a qualitative in vitro diagnostic test (CE-IVD) that detects variants in 1021 tumor-related genes and gene rearrangements
/ fusions in 38 genes.

It analyzes biomarkers for immunotherapy response, including detection of HLA
and biomarkers for chemotherapy response. MGI-DNBSEQ-G400 is a CE-IVD platform which allows the simultaneous processing of multiple samples with high sensitivity and specificity thus producing
faster, reliable results at a lower cost

2020 Genekor Medical S.A.. All Rights Reserved.

Web Design